Tumor-Specific Neoantigen Peptides (TSNs)

Tumor-specific neoantigen peptides (TSNs) are short protein fragments derived from somatic mutations found exclusively in tumor cells. Presented on MHC molecules, they are recognized by T cells, making them promising targets for personalized cancer immunotherapies like vaccines and adoptive cell therapies. They elicit strong anti-tumor immune responses because they are absent from normal tissues, minimizing the risk of autoimmunity. Identification involves sequencing tumor DNA/RNA, predicting peptide-HLA binding, and validating immunogenicity. Challenges remain in optimizing epitope selection and overcoming tumor resistance mechanisms.

Other names

NeoantigensTumor-specific antigensMutated tumor antigensNeopeptides

TSNs are presented on MHC molecules and recognized by T cell receptors (TCRs), leading to T cell activation and tumor cell lysis.